D. Barone

Identification and Characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3 S)thiomorpholinecarboxamide (TMI-1), a Novel Dual Tumor Necrosis Factor-α-Converting Enzyme/Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis

Yuhua Zhang, Jun Xu, Jeremy I. Levin et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 91 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1′ group

Jeremy I. Levin, J.M Chen, Mingyang Du et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 75 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +6

Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates

Jeremy I. Levin, J.M. Chen, Leif M. Laakso et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 54 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +5

Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates

Jeremy I. Levin, J.M. Chen, Katherine Cheung et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 49 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +7

CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells

Martha Hayden-Ledbetter, C. Cerveny, Erik Espling et al. · Clinical Cancer Research · 2009 · 46 citations · Full text

Medicine, Immunology, Pharmacology +14